Refile: BUZZ-China's Hansoh Pharma rises on Roche licensing deal

Hansoh Pharmaceutical

17/10/2025 04:02

Corrects to remove extraneous word in headline

** Hansoh Pharmaceutical Group 3692.HK rises 5.1% to HK$37.58; set for biggest one-day pct gain since October 2

** Stock on course for third straight session of gains; sixth biggest pct gainer on healthcare index .HSCIH, which is down 1.1%

** Chinese biotech group signs licence agreement worth up to $1.45 bln with Roche ROG.S for investigational treatment of colorectal cancer, other solid tumours

** Hansoh units Shanghai Hansoh Biomedical, Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche exclusive worldwide licence to develop, manufacture, commercialise product

** YTD, Hansoh stock soars 115.3%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))